One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Kathleen McGroddy-Goetz net worth and biography

Kathleen McGroddy-Goetz Biography and Net Worth

Director of Tandem Diabetes Care

Dr. McGroddy-Goetz has served on our board of directors since June 2020. She has more than 25 years of experience leading global teams across business development, strategy, research and development, and product management. She has commercialized pioneering technologies spanning from microelectronics through cloud, advanced data analytics, artificial intelligence, hardware, software, and middleware with an emphasis on healthcare and life sciences applications. From October 2018 through June 2021, Dr. McGroddy-Goetz served as the Global Head of Strategic Partnerships at Medidata Solutions, a Dassault Systemès Company, where she also concurrently held other strategy, alliances and marketing executive roles. Previously, she held various leadership positions at IBM beginning in 1992, and most recently was Vice President, Strategy and Innovation, IBM Watson Health. Dr. McGroddy-Goetz received a B.S. in Physics from SUNY Binghamton and a Ph.D. in Molecular Biophysics from Cornell University.

What is Kathleen McGroddy-Goetz's net worth?: The estimated net worth of Kathleen McGroddy-Goetz is at least $278,095.28 as of September 15th, 2023. Dr. McGroddy-Goetz owns 9,032 shares of Tandem Diabetes Care stock worth more than $278,095 as of April 19th. This net worth approximation does not reflect any other investments that Dr. McGroddy-Goetz may own. Learn More about Kathleen McGroddy-Goetz's net worth.
How do I contact Kathleen McGroddy-Goetz?: The corporate mailing address for Dr. McGroddy-Goetz and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at [email protected]. Learn More on Kathleen McGroddy-Goetz's contact information.
Has Kathleen McGroddy-Goetz been buying or selling shares of Tandem Diabetes Care?: Kathleen McGroddy-Goetz has not been actively trading shares of Tandem Diabetes Care over the course of the past ninety days. Most recently, on Friday, September 15th, Kathleen Mcgroddy-Goetz bought 1,000 shares of Tandem Diabetes Care stock. The stock was acquired at an average cost of $21.45 per share, with a total value of $21,450.00. Following the completion of the transaction, the director now directly owns 9,032 shares of the company's stock, valued at $193,736.40. Learn More on Kathleen McGroddy-Goetz's trading history.
Who are Tandem Diabetes Care's active insiders?: Tandem Diabetes Care's insider roster includes David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.
Are insiders buying or selling shares of Tandem Diabetes Care?: In the last twelve months, Tandem Diabetes Care insiders bought shares 6 times. They purchased a total of 27,150 shares worth more than $635,045.95. The most recent insider tranaction occured on November, 27th when Director Dick Allen bought 5,000 shares worth more than $94,800.00. Insiders at Tandem Diabetes Care own 2.5% of the company. Learn More about insider trades at Tandem Diabetes Care.
Information on this page was last updated on 11/27/2023.

Kathleen McGroddy-Goetz Insider Trading History at Tandem Diabetes Care

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/15/2023	Buy	1,000	$21.45	$21,450.00	9,032
3/14/2022	Sell	405	$106.00	$42,930.00

Kathleen McGroddy-Goetz Buying and Selling Activity at Tandem Diabetes Care

Tandem Diabetes Care Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $30.37

$30.27

$31.39

50 Day Range

MA: $29.80

$22.55

$35.41

2 Week Range

Now: $30.37

$13.82

$40.92

Volume

546,483 shs

Average Volume

1,736,662 shs

Market Capitalization

$1.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Strange new buyer driving up gold

From Stansberry Research | Ad